Related Experiment Video
Updated: Aug 5, 2026
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Intravenous Cangrelor Versus Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Endovascular Thrombectomy for
Muhammed Amir Essibayi1, Ahmed Y Azzam2, Bluyé DeMessie2
1From the Department of Neurological Surgery (M.A.E., B.D.M., A.P.T., N.H., D.J.A.), Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY, USA; Department of Neuroradiology (A.Y.A., J.K., H.J., B.C., M.B., D.A.L.), Neurology (D.M.), Rockefeller Neuroscience Institute, Radiology (B.C., M.B.), West Virginia University, Morgantown, WV, USA; Department of Neuroradiology (H.A.C.), MD Anderson Cancer Center, Houston, TX, USA; Graduate School of Public Health (H. J.), St Luke's International University, Tokyo, Japan; Department of Neurosurgery (H.C., D.G.), University of Maryland Medical Center, Baltimore, MD, USA; Department of Radiology (P.R.), Mayo Clinic, Rochester, MN, USA; Department of Neurosurgery (M.K.M.), Interventional Radiology (M.C.), Oregon Health and Science University, Portland, OR, USA; Division of Neuroradiology (V.S.Y., M.K.), Department of Radiology and Radiological Sciences, Johns Hopkins University, Baltimore, MD, USA; Nuffield Department of Surgical Sciences (A.A.D.), Medical Sciences Division, University of Oxford, Oxford, UK; Neurointerventional & Neuroanalytics Collaboration (NAN-C) (A.A.D.), School of Medicine, Toronto Metropolitan University, Toronto, ON, Canada; Neuroendovascular Program (A.A. D.), Massachusetts General Hospital & Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Department of Radiology (A.M.), Yale New Haven Hospital, New Haven, CT, USA; Department of Neurosurgery (S.A.K.), Medical University of South Carolina, Charleston, SC, USA and Neuroendovascular Surgery (M.E.), HCA Houston, Houston, Texas, USA. m.amir.essibayi@gmail.com.
Background:
Antiplatelet therapy is frequently used during endovascular thrombectomy (EVT) for middle cerebral artery (MCA) stroke, particularly when intracranial stenting is required. This study compared clinical outcomes between intravenous cangrelor and glycoprotein IIb/IIIa inhibitors (GPIs) in patients undergoing EVT for MCA stroke.
Methods:
Using the TriNetX research network (113 healthcare organizations), we identified adult patients with MCA stroke who underwent EVT between January 2016 and January 2026 and received concomitant cangrelor or GPIs. Propensity score matching (1:1) was performed to balance baseline characteristics. Primary outcomes included major bleeding, intracranial hemorrhage (ICH), and decompressive hemicraniectomy. Prespecified subgroup analysis stratified patients by adjunctive angioplasty/stenting.
Results:
After matching, 302 patients remained in each group. In the overall cohort, no significant differences were observed in major bleeding (18.9% vs 24.5%; HR 0.74, P=0.084), ICH (17.9% vs 22.5%; HR 0.77, P=0.14), or mortality (17.2% vs 14.9%; HR 1.13, P=0.55). However, in the angioplasty/stenting subgroup (n=98 per group), cangrelor appeared to be associated with lower rates of major bleeding (15.3% vs 26.5%; HR 0.53, 95% CI 0.28-1.01, P=0.047), ICH (14.3% vs 25.5%; HR 0.52, P=0.04), decompressive hemicraniectomy (17.3% vs 31.6%; HR 0.52, P=0.02), and functional dependency (18.4% vs 31.6%; HR 0.50, P=0.02), but higher recurrent stroke at 1-24 months (32.7% vs 11.2%; HR 2.57, P<0.01). No difference in outcomes was found in the no angioplasty group.
Conclusions:
Both drugs demonstrated comparable outcomes overall. In an exploratory angioplasty/stenting subgroup, cangrelor was associated with reduced hemorrhagic complications but increased recurrent stroke, suggesting a complex risk-benefit tradeoff requiring individualized antiplatelet selection.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care